BioLineRx Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioLineRx in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BioLineRx stock.
View analyst ratings for BioLineRx or view top-rated stocks.

Wall Street analysts have given BioLineRx a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but BioLineRx wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

BioLineRx saw a increase in short interest in the month of May. As of May 14th, there was short interest totaling 559,500 shares, an increase of 27.6% from the April 29th total of 438,500 shares. Based on an average trading volume of 5,150,000 shares, the short-interest ratio is presently 0.1 days.
View BioLineRx's Short Interest.

BioLineRx is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for BioLineRx.

BioLineRx Ltd. (NASDAQ:BLRX) issued its quarterly earnings results on Monday, November, 23rd. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.36) by $0.06.
View BioLineRx's earnings history.

BioLineRx's stock was trading at $1.60 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, BLRX stock has increased by 66.9% and is now trading at $2.67.
View which stocks have been most impacted by COVID-19.

2 brokers have issued 12-month price objectives for BioLineRx's shares. Their forecasts range from $10.00 to $19.00. On average, they anticipate BioLineRx's share price to reach $14.50 in the next twelve months. This suggests a possible upside of 443.1% from the stock's current price.
View analysts' price targets for BioLineRx or view top-rated stocks among Wall Street analysts.

Some companies that are related to BioLineRx include Basilea Pharmaceutica (BPMUF), Vaccitech (VACC), SIGA Technologies (SIGA), Viking Therapeutics (VKTX), XBiotech (XBIT), Molecular Templates (MTEM), Landos Biopharma (LABP), Nabriva Therapeutics (NBRV), Greenwich LifeSciences (GLSI), Viracta Therapeutics (VIRX), TherapeuticsMD (TXMD), CytomX Therapeutics (CTMX), Gemini Therapeutics (GMTX), Avadel Pharmaceuticals (AVDL) and Flexion Therapeutics (FLXN).
View all of BLRX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other BioLineRx investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Zosano Pharma (ZSAN), KushCo (KSHB), Aeterna Zentaris (AEZS), Cannabics Pharmaceuticals (CNBX), Pennsylvania Real Estate Investment Trust (PEI), Savara (SVRA), Bionano Genomics (BNGO) and Gran Tierra Energy (GTE).

BioLineRx trades on the NASDAQ under the ticker symbol "BLRX."

BioLineRx's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (1.17%), Morgan Stanley (0.88%), Silverarc Capital Management LLC (0.46%), Schonfeld Strategic Advisors LLC (0.18%), Intellectus Partners LLC (0.09%) and Game Plan Financial Advisors LLC (0.06%).

BLRX stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley.

BLRX stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Silverarc Capital Management LLC, Schonfeld Strategic Advisors LLC, Intellectus Partners LLC, Game Plan Financial Advisors LLC, Goldman Sachs Group Inc., and First Heartland Consultants Inc..

Shares of BLRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BLRX stock can currently be purchased for approximately $2.67.

BioLineRx has a market capitalization of $121.53 million. The biotechnology company earns $-30,020,000.00 in net income (profit) each year or ($1.80) on an earnings per share basis.

BioLineRx employs 38 workers across the globe.

The official website for BioLineRx is www.biolinerx.com.

BioLineRx is headquartered at 2 HAMA-AYAN STREET, MODI-IN L3, 7177871.

BioLineRx's mailing address is 2 HAMA-AYAN STREET, MODI-IN L3, 7177871. The biotechnology company can be reached via phone at 972-8642-9100 or via email at [email protected]